BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2258577)

  • 1. HLA-DR4 associated response to corticosteroids in Graves' ophthalmopathy patients.
    van der Gaag R; Wiersinga WM; Koornneef L; Mourits MP; Prummel MF; Berghout A; de Vries RR; Schreuder GM; D'Amaro J
    J Endocrinol Invest; 1990 Jun; 13(6):489-92. PubMed ID: 2258577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of HLA antigen BW35 with severe Graves' ophthalmopathy.
    Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ; Sanford CA
    Invest Ophthalmol Vis Sci; 1983 Jan; 24(1):124-7. PubMed ID: 6600737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DR associations with Graves' disease in eastern Hungary.
    Stenszky V; Kozma L; Balazs C; Farid NR
    Clin Invest Med; 1983; 6(3):181-4. PubMed ID: 6580983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
    Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
    Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic differences shown by HLA typing among Japanese patients with euthyroid Graves' ophthalmopathy, Graves' disease and Hashimoto's thyroiditis: genetic characteristics of euthyroid Graves' ophthalmopathy.
    Inoue D; Sato K; Maeda M; Inoko H; Tsuji K; Mori T; Imura H
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):57-62. PubMed ID: 2004473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciclosporine and Graves' ophthalmopathy.
    Gayno JP; Strauch G
    Horm Res; 1987; 26(1-4):190-7. PubMed ID: 3596468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with Graves' disease who developed insulin autoimmune syndrome (Hirata disease) possess HLA-Bw62/Cw4/DR4 carrying DRB1*0406.
    Uchigata Y; Kuwata S; Tsushima T; Tokunaga K; Miyamoto M; Tsuchikawa K; Hirata Y; Juji T; Omori Y
    J Clin Endocrinol Metab; 1993 Jul; 77(1):249-54. PubMed ID: 8325948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA and autoimmune endocrine disease 1985.
    Farid NR; Thompson C
    Mol Biol Med; 1986 Feb; 3(1):85-97. PubMed ID: 3485759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of HLA types and clinical findings in Japanese patients with hyperthyroid Graves' disease: evidence indicating the existence of four subpopulations.
    Inoue D; Sato K; Enomoto T; Sugawa H; Maeda M; Inoko H; Tsuji K; Mori T; Imura H
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):75-82. PubMed ID: 1559302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic factors in Graves' ophthalmopathy.
    Frecker M; Stenszky V; Balazs C; Kozma L; Kraszits E; Farid NR
    Clin Endocrinol (Oxf); 1986 Nov; 25(5):479-85. PubMed ID: 3113776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human lymphocyte antigens (HLA) and Graves' disease in Turkey.
    Orhan Y; Azezli A; Carin M; Aral F; Sencer E; Molvalilar S
    J Clin Immunol; 1993 Sep; 13(5):339-43. PubMed ID: 7902362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of immune damage in Graves' ophthalmopathy.
    Hiromatsu Y; Wang PW; Wosu L; How J; Wall JR
    Horm Res; 1987; 26(1-4):198-207. PubMed ID: 3596469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of autoimmune ophthalmopathy from Graves' hyperthyroidism by analysis of genetic markers.
    Kendall-Taylor P; Stephenson A; Stratton A; Papiha SS; Perros P; Roberts DF
    Clin Endocrinol (Oxf); 1988 Jun; 28(6):601-10. PubMed ID: 3254259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class III alleles and high-risk MHC haplotypes in type I diabetes mellitus, Graves' disease and Hashimoto's thyroiditis.
    Skanes VM; Barnard J; Farid N; Marshall WH; Murphy L; Rideout D; Taylor R; Xidos G; Larsen B
    Mol Biol Med; 1986 Apr; 3(2):143-57. PubMed ID: 3461234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
    de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenetics of Graves' ophthalmopathy.
    Weetman AP; So AK; Warner CA; Foroni L; Fells P; Shine B
    Clin Endocrinol (Oxf); 1988 Jun; 28(6):619-28. PubMed ID: 2908181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy].
    Yang H; Wu Z; Huang X; Xie C; Yang P
    Yan Ke Xue Bao; 1999 Jun; 15(2):78-80. PubMed ID: 12579704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human leukocyte antigens associated with hyperthyroid Graves ophthalmology in Japanese patients.
    Ohtsuka K; Nakamura Y
    Am J Ophthalmol; 1998 Dec; 126(6):805-10. PubMed ID: 9860004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
    Bednarek J; Wysocki H; SowiƄski J
    Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major histocompatibility complex (MHC) factors predisposing to and protecting against Graves' eye disease.
    Frecker M; Mercer G; Skanes VM; Farid NR
    Autoimmunity; 1988; 1(4):307-15. PubMed ID: 2979624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.